Central hypotensive effects of the α(2a)-adrenergic receptor subtype

Science

Volumn 273, Issue 5276, 1996, Pages 801-803

  MacMillan, Leigh B ^a   Hein, Lutz ^b   Smith, Marta S ^c   Piascik, Michael T ^c   Limbird, Lee E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; BRIMONIDINE; DEXMEDETOMIDINE; IMIDAZOLINE RECEPTOR; PRAZOSIN; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; BRAIN STEM; CONTROLLED STUDY; DRUG EFFECT; GENE TARGETING; GENOME; HYPERTENSION; HYPOTENSION; INTRAARTERIAL DRUG ADMINISTRATION; MOUSE; MOUSE MUTANT; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0029777474     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5276.801     Document Type: Article

References (27)

1. R. R. Ruffolo, A. J. Nichols, J. M. Stadel, J. P. Hieble, Annu. Rev. Pharmacol. Toxicol. 32, 243 (1993).
2. P. Bousquet et al., Am. J. Hypertens. 5, 47S (1992).
3. G. Li et al., Science 263, 966 (1994).
4. D. B. Bylund et al., Pharmacol. Rev. 46, 121 (1994).
5. A. P. Nicholas, V. Pieribone, T. Hokfelt, J. Comp. Neurol. 328, 575 (1993); S. K. McCune, M. M. Voigt, J. M. Hill, Neuroscience 57, 143 (1993); M. Scheinin et al., Mol. Brain Res. 21, 133 (1994); R. Wang et al., Neuroscience, in press.
6. A. P. Nicholas, V. Pieribone, T. Hokfelt, J. Comp. Neurol. 328, 575 (1993); S. K. McCune, M. M. Voigt, J. M. Hill, Neuroscience 57, 143 (1993); M. Scheinin et al., Mol. Brain Res. 21, 133 (1994); R. Wang et al., Neuroscience, in press.
7. A. P. Nicholas, V. Pieribone, T. Hokfelt, J. Comp. Neurol. 328, 575 (1993); S. K. McCune, M. M. Voigt, J. M. Hill, Neuroscience 57, 143 (1993); M. Scheinin et al., Mol. Brain Res. 21, 133 (1994); R. Wang et al., Neuroscience, in press.
8. A. P. Nicholas, V. Pieribone, T. Hokfelt, J. Comp. Neurol. 328, 575 (1993); S. K. McCune, M. M. Voigt, J. M. Hill, Neuroscience 57, 143 (1993); M. Scheinin et al., Mol. Brain Res. 21, 133 (1994); R. Wang et al., Neuroscience, in press.
9. L. F, Kolakowski, Receptors Channels 2, 1 (1994).
10. A. Surprenant, D. A. Horstman, H. Akbarali, L. E. Limbird, Science 257, 977 (1992).
11. R. Ramirez-Solis, A. C. Davis, A. Bradley, Methods Enzymol. 225, 855 (1993).
12. D. A. Horstman et al., J. Biol. Chem. 265, 21590 (1990).
13. 2aAR (9).
14. R. E. Link et al., Science 273, 803 (1996).
15. O. Chabre, B. R. Conklin, S. Brandon, H. R. Bourne, L. E. Limbird, J. Biol. Chem. 269, 5730 (1994).
16. 3H]RX 821002. Nonspecific binding was defined as binding not displaced by 10 μM phentolamine (14). Nonlinear regression fit of the data was done with GraphPad Prism software.
17. B. P. Ceresa and L. E. Limbird, J. Biol. Chem. 269, 29557 (1994).
18. P, Soriano, C. Montgomery, R. Geske, A. Bradley, Cell 64, 693 (1991).
19. F. M. Ausubel et al. ,Eds., Current Protocols in Molecular Biology (Wiley, New York, 1989), Unit 4.7.
20. P. E. Danielson et al., DNA 7, 261 (1988).
21. tmtLet.
22. 2aAR coding sequence [base pairs (bp) 113 to 385] from wild-type and D79N mouse tail DNA was amplified by polymerase chain reaction (PCR) and subcloned into pBluescriptll SK(+). Multiple transformants were sequenced with Sequenase 2.0 (USB).
23. J P. Hieble, W. E. Bondinell, R. R. Ruffolo, J. Med. Chem. 38, 3415 (1995).
24. L. B. MacMillan and L. E. Limbird, unpublished data.
25. 2aAR coding region, was amplified by PCR and subcloned into pBluescriptll KS(+). Total brain RNA (2 μg), isolated from 2-monthold mice, was used in the protection assays. Singlestranded RNA was digested with RNase A (5 μg/ml); wild-type RNA was also digested with RNase A at the site of the mutation, resulting in the smaller expected wild-type fragment. The cyclophilin probe, bp 40 to 146 of rat cyclophilin (17), was from R. B. Emeson (Vanderbilt University). Probe excess was confirmed in incubations containing 4 and 8 μg of total RNA. Phosphorlmager analysis (Molecular Dynamics) was used to quantitate RNA.
26. 2AR agonists were injected directly into the arterial catheter in a 10-μl bolus. For the femoral catheter experiments, a Microrenathane (0.064 cm outer diameter, 0.030 cm inner diameter cannula; Braintree Scientific) was inserted into the femoral artery of anesthetized male mice (2 to 3 months old). Mice recovered for 4 to 6 hours before arterial blood pressure was recorded on a Grass Model 7 polygraph by means of a Cobe blood pressure transducer. Heart rate was calculated from blood pressure tracings. UK 14,304 was injected into the arterial catheter; each sequential dose of UK 14,304 was injected after the blood pressure of wild-type mice had returned to baseline or after a comparable time (about 5 min) for D79N mice. Vehicle injection had no effect on the recorded cardiovascular responses.
27. Supported by National Institutes of Health grants HL43671 (to L.E.L.), HL38120 (to M.T.P.), and HL48638 (Project 4) (to B. K. Kobilka in support of L.H.); by a Vanderbilt University Graduate Fellowship (to L.B.M.); and by an Established Investigator Award from the National Association for Research on Schizophrenia and Depression (to L.E.L.).